- Home
- XRTX vs SONN Comparison
XRTX vs SONN Comparison
Compare XRTX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- SONN
- Stock Information
- Founded
- XRTX 2011
- SONN N/A
- Country
- XRTX Canada
- SONN United States
- Employees
- XRTX N/A
- SONN N/A
- Industry
- XRTX Pharmaceuticals and Biotechnology
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- XRTX Health Care
- SONN Health Care
- Exchange
- XRTX Nasdaq
- SONN Nasdaq
- Market Cap
- XRTX 3.0M
- SONN 2.5M
- IPO Year
- XRTX N/A
- SONN N/A
- Fundamental
- Price
- XRTX $0.92
- SONN $1.36
- Analyst Decision
- XRTX
- SONN Strong Buy
- Analyst Count
- XRTX 0
- SONN 2
- Target Price
- XRTX N/A
- SONN $38.00
- AVG Volume (30 Days)
- XRTX 84.2K
- SONN 70.3K
- Earning Date
- XRTX 05-09-2025
- SONN 02-13-2025
- Dividend Yield
- XRTX N/A
- SONN N/A
- EPS Growth
- XRTX N/A
- SONN N/A
- EPS
- XRTX N/A
- SONN N/A
- Revenue
- XRTX N/A
- SONN $1,000,000.00
- Revenue This Year
- XRTX N/A
- SONN N/A
- Revenue Next Year
- XRTX N/A
- SONN N/A
- P/E Ratio
- XRTX N/A
- SONN N/A
- Revenue Growth
- XRTX N/A
- SONN 674.14
- 52 Week Low
- XRTX $0.82
- SONN $1.30
- 52 Week High
- XRTX $5.81
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- XRTX 42.89
- SONN 36.67
- Support Level
- XRTX $0.85
- SONN $1.30
- Resistance Level
- XRTX $1.10
- SONN $1.52
- Average True Range (ATR)
- XRTX 0.11
- SONN 0.09
- MACD
- XRTX 0.00
- SONN -0.00
- Stochastic Oscillator
- XRTX 11.63
- SONN 30.22
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.